Literature DB >> 28132544

Growing challenges for HIV programmes in Asia: clinic population trends, 2003-2013.

Nicole L De La Mata1, Nagalingeswaran Kumarasamy2, Penh Sun Ly3, Oon Tek Ng4, Kinh Van Nguyen5, Tuti Parwati Merati6, Man Po Lee7, Cuong Duy Do8, Jun Yong Choi9, Jeremy L Ross10, Matthew G Law1.   

Abstract

The scale-up of antiretroviral therapy (ART) has led to a substantial change in the clinical population of HIV-positive patients receiving care. We describe the temporal trends in the demographic and clinical characteristics of HIV-positive patients initiating ART in 2003-13 within an Asian regional cohort. All HIV-positive adult patients that initiated ART between 2003 and 2013 were included. We summarized ART regimen use, age, CD4 cell count, HIV viral load, and HIV-related laboratory monitoring rates during follow-up by calendar year. A total of 16 962 patients were included in the analysis. Patients in active follow-up increased from 695 patients at four sites in 2003 to 11,137 patients at eight sites in 2013. The proportion of patients receiving their second or third ART regimen increased over time (5% in 2003 to 29% in 2013) along with patients aged ≥50 years (8% in 2003 to 18% in 2013). Concurrently, CD4 monitoring has remained stable in recent years, whereas HIV viral load monitoring, although varied among the sites, is increasing. There have been substantial changes in the clinical and demographic characteristics of HIV-positive patients receiving ART in Asia. HIV programmes will need to anticipate the clinical care needs for their aging populations, expanded viral load monitoring, and, the eventual increase in second and third ART regimens that will lead to higher costs and more complex drug procurement needs.

Entities:  

Keywords:  ART; Asia; HIV; characteristics; clinical; demographics

Mesh:

Substances:

Year:  2017        PMID: 28132544      PMCID: PMC5534184          DOI: 10.1080/09540121.2017.1282108

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  32 in total

1.  HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group.

Authors:  Kevin P High; Mark Brennan-Ing; David B Clifford; Mardge H Cohen; Judith Currier; Steven G Deeks; Sherry Deren; Rita B Effros; Kelly Gebo; Jörg J Goronzy; Amy C Justice; Alan Landay; Jules Levin; Paolo G Miotti; Robert J Munk; Heidi Nass; Charles R Rinaldo; Michael G Shlipak; Russell Tracy; Victor Valcour; David E Vance; Jeremy D Walston; Paul Volberding
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

2.  Benefit of viral load testing for confirmation of immunological failure in HIV patients treated in rural Malawi.

Authors:  Rupa Kanapathipillai; Megan McGuire; Robert Mogha; Elisabeth Szumilin; Annette Heinzelmann; Mar Pujades-Rodríguez
Journal:  Trop Med Int Health       Date:  2011-09-01       Impact factor: 2.622

Review 3.  The clinical implications of HIV infection and aging.

Authors:  M John
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

4.  Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.

Authors:  Kim C E Sigaloff; Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Prudence Ive; Mariette E Botes; Kishor Mandaliya; Maureen Wellington; Akin Osibogun; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit
Journal:  J Acquir Immune Defic Syndr       Date:  2011-09-01       Impact factor: 3.731

5.  Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.

Authors:  Mar Pujades-Rodríguez; Suna Balkan; Line Arnould; Martin A W Brinkhof; Alexandra Calmy
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

6.  Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis.

Authors:  S Teeraananchai; S J Kerr; J Amin; K Ruxrungtham; M G Law
Journal:  HIV Med       Date:  2016-08-31       Impact factor: 3.180

7.  Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.

Authors:  Françoise Renaud-Théry; Boniface Dongmo Nguimfack; Marco Vitoria; Evan Lee; Peter Graaff; Badara Samb; Joseph Perriëns
Journal:  AIDS       Date:  2007-07       Impact factor: 4.177

8.  Monitoring HIV viral load in resource limited settings: still a matter of debate?

Authors:  Mireia Arnedo; Elena Alonso; Nell Eisenberg; Laura Ibáñez; Cecilia Ferreyra; Angels Jaén; Laurence Flevaud; Samuel Khamadi; Paul Roddy; Jose Maria Gatell; David Dalmau
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

Review 9.  The next therapeutic challenge in HIV: polypharmacy.

Authors:  E Jennifer Edelman; Kirsha S Gordon; Janis Glover; Ian R McNicholl; David A Fiellin; Amy C Justice
Journal:  Drugs Aging       Date:  2013-08       Impact factor: 3.923

Review 10.  Polypharmacy in the HIV-infected older adult population.

Authors:  Lauren J Gleason; Amneris E Luque; Krupa Shah
Journal:  Clin Interv Aging       Date:  2013-06-21       Impact factor: 4.458

View more
  1 in total

1.  Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China.

Authors:  Peng-Le Guo; Hao-Lan He; Xie-Jie Chen; Jin-Feng Chen; Xiao-Ting Chen; Yun Lan; Jian Wang; Pei-Shan Du; Huo-Lin Zhong; Hong Li; Cong Liu; Li-Ya Li; Feng-Yu Hu; Xiao-Ping Tang; Wei-Ping Cai; Ling-Hua Li
Journal:  Front Pharmacol       Date:  2021-03-25       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.